Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer

worldpharmanewsJanuary 16, 2020

Tag: Lynparza , Bevacizumab , ovarian cancer , AstraZeneca , msd

PharmaSources Customer Service